For most of a decade, I worked on the commercial side of life sciences, and the same thing kept happening. Something would change at an account. A financing would close, a trial would move into a new phase, or a facility would receive an inspection observation. I...
A new therapeutic can take a decade. Often hundreds of millions of dollars. Regulators checking the work at every stage along the way. So when a category of founders consistently delivers better returns on less capital, you'd expect investment patterns to reflect...
A research team at the University of Colorado Boulder took a marine dinoflagellate called Pyrocystis lunula, mixed it into 4 wt% sodium alginate, crosslinked the gel ionically in calcium chloride, and extruded it through a Cellink BIO X bioprinter into printed grids...
For decades, the fields of oncology, neuroscience, and microbiology operated in distinct silos within therapeutic research and clinical practice. Modern drug discovery, however, is rapidly witnessing a paradigm shift toward systemic biology. Researchers increasingly...
Immuno-oncology is not a new frontier, and for years, therapies like checkpoint inhibitors have reshaped how we treat certain cancers. While early approaches established that the immune system could fight cancer, the field has seen both major breakthroughs and clear...
The first half of 2026 has delivered a decisive answer to a question the life sciences industry has been asking for years: is the biotech IPO window finally open again? The drought bottomed out in 2025, when fewer biotechs went public than in any year in at least half...
For decades, obesity has been defined and diagnosed primarily using body mass index (BMI), a simple ratio of weight to height. While BMI has been widely adopted for its convenience and scalability, a growing body of research now suggests that it may be an incomplete...
Spinal cord injuries remain one of the most challenging conditions in modern medicine. Damage to the spinal cord often leads to permanent paralysis, loss of sensation, and a dramatic decline in quality of life. For decades, treatment options have been limited to...
Basecamp Research, a frontier AI lab harnessing evolution to design new medicines, today announced the first AI models capable of programmable gene insertion, offering a new way to replace faulty genes and reprogram cells for therapeutic use. Trained in collaboration...
Peptides are no longer confined to the margins of biomedical research. Once viewed primarily as niche tools for probing biological pathways or as incremental drug candidates, peptides and related biomolecules are now emerging as a central pillar of innovation across...
How Modular Hardware Is Breaking Decades of Vendor Lock-In There’s a running joke among biotech lab managers that goes something like this: You don’t buy a bioreactor. You buy a relationship. A very expensive, very locked-in relationship. It’s funny because it’s...
India is emerging as one of the most dynamic life sciences markets in the world. Long recognised for its strength in pharmaceuticals and generics, the country is now experiencing a broader life sciences boom that spans biotechnology, vaccines, medical devices,...
Swiss biotechnology company Windward Bio has entered into a significant licensing agreement with Chinese biotech Qyuns Therapeutics, securing rights outside China to a clinical stage immunology bispecific antibody known as WIN027, also referred to as QX027N. The...
Artificial intelligence is increasingly being judged on clinical progress and tangible outcomes, not just models and algorithms. Once a speculative concept, AI-driven drug discovery is now generating real-world data, advancing molecules into human studies, reshaping...
The landscape of global disease continues to evolve, shaped by demographic shifts, environmental pressures, and rapid advances in biomedical innovation. For life science professionals, understanding where the world’s highest-burden diseases stand today, and where...
The biotechnology sector is navigating a turbulent market environment in 2025. After earlier highs, many biotech companies have seen steep share-price declines, while investors remain cautious yet selective about which assets to back. As macroeconomic pressures and...
The field of obesity treatment is expanding beyond GLP 1 receptor agonists as a growing wave of gene modulating and RNA based therapies emerges. These next generation programmes aim to address fat accumulation, particularly visceral fat and metabolic dysfunction,...
One of the biggest surprises in modern cancer biology is that tumors are wired with nerves—and cancers with more nerve fibers tend to be more aggressive. A new study finally explains why. The Key Finding Neurons actively transfer their mitochondria — the cell’s energy...